Search research articles
Contact Us
Filters
Showing results (511-520 of 520) with videos related to
Page
of 52
Sort By:
You have reached the last page of results.
This site can display upto 520 results.
Trials
|
December 28, 2022
Safety and microbiological activity of phage therapy in persons with cystic fibrosis colonized with Pseudomonas aeruginosa: study protocol for a phase 1b/2, multicenter, randomized, double-blind, placebo-controlled trial
Pranita D Tamma, Maria Souli, Michael Billard, et al.
Antimicrobial Agents and Chemotherapy
|
February 8, 2017
Can Ceftazidime-Avibactam and Aztreonam Overcome β-Lactam Resistance Conferred by Metallo-β-Lactamases in Enterobacteriaceae?
Steven Marshall, Andrea M Hujer, Laura J Rojas, et al.
Open Forum Infectious Diseases
|
November 16, 2022
Clinical Impact of Ceftriaxone Resistance in <i>Escherichia coli</i> Bloodstream Infections: A Multicenter Prospective Cohort Study
Pranita D Tamma, Lauren Komarow, Lizhao Ge, et al.
The New England Journal of Medicine
|
August 18, 2006
Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus
Vance G Fowler, Helen W Boucher, G Ralph Corey, et al.
Antimicrobial Agents and Chemotherapy
|
May 15, 2026
Resistance to novel β-lactam/β-lactamase inhibitors among carbapenem-resistant <i>Pseudomonas aeruginosa</i> and clinical implications in the prospective observational <i>Pseudomonas</i> study
Lee S Gottesdiener, Yixuan Li, Kerryl E Greenwood-Quaintance, et al.
The Lancet. Infectious Diseases
|
March 11, 2020
Molecular and clinical epidemiology of carbapenem-resistant Enterobacterales in the USA (CRACKLE-2): a prospective cohort study
David van Duin, Cesar A Arias, Lauren Komarow, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
September 22, 2023
Clinical Outcomes and Bacterial Characteristics of Carbapenem-resistant Acinetobacter baumannii Among Patients From Different Global Regions
Minggui Wang, Lizhao Ge, Liang Chen, et al.
The Lancet. Infectious Diseases
|
November 12, 2021
Clinical outcomes and bacterial characteristics of carbapenem-resistant Klebsiella pneumoniae complex among patients from different global regions (CRACKLE-2): a prospective, multicentre, cohort study
Minggui Wang, Michelle Earley, Liang Chen, et al.
The Lancet. Microbe
|
February 12, 2023
Global epidemiology and clinical outcomes of carbapenem-resistant Pseudomonas aeruginosa and associated carbapenemases (POP): a prospective cohort study
Jinnethe Reyes, Lauren Komarow, Liang Chen, et al.
JAMA
|
August 13, 2025
Dalbavancin for Treatment of Staphylococcus aureus Bacteremia: The DOTS Randomized Clinical Trial
Nicholas A Turner, Toshimitsu Hamasaki, Sarah B Doernberg, et al.
Page
of 52
Search research articles
Search
Showing results (511-520 of 520) with videos related to
Sort By:
Page
of 52
You have reached the last page of results.
This site can display upto 520 results.
Trials
|
December 28, 2022
Safety and microbiological activity of phage therapy in persons with cystic fibrosis colonized with Pseudomonas aeruginosa: study protocol for a phase 1b/2, multicenter, randomized, double-blind, placebo-controlled trial
Pranita D Tamma, Maria Souli, Michael Billard, et al.
Antimicrobial Agents and Chemotherapy
|
February 8, 2017
Can Ceftazidime-Avibactam and Aztreonam Overcome β-Lactam Resistance Conferred by Metallo-β-Lactamases in Enterobacteriaceae?
Steven Marshall, Andrea M Hujer, Laura J Rojas, et al.
Open Forum Infectious Diseases
|
November 16, 2022
Clinical Impact of Ceftriaxone Resistance in <i>Escherichia coli</i> Bloodstream Infections: A Multicenter Prospective Cohort Study
Pranita D Tamma, Lauren Komarow, Lizhao Ge, et al.
The New England Journal of Medicine
|
August 18, 2006
Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus
Vance G Fowler, Helen W Boucher, G Ralph Corey, et al.
Antimicrobial Agents and Chemotherapy
|
May 15, 2026
Resistance to novel β-lactam/β-lactamase inhibitors among carbapenem-resistant <i>Pseudomonas aeruginosa</i> and clinical implications in the prospective observational <i>Pseudomonas</i> study
Lee S Gottesdiener, Yixuan Li, Kerryl E Greenwood-Quaintance, et al.
The Lancet. Infectious Diseases
|
March 11, 2020
Molecular and clinical epidemiology of carbapenem-resistant Enterobacterales in the USA (CRACKLE-2): a prospective cohort study
David van Duin, Cesar A Arias, Lauren Komarow, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
September 22, 2023
Clinical Outcomes and Bacterial Characteristics of Carbapenem-resistant Acinetobacter baumannii Among Patients From Different Global Regions
Minggui Wang, Lizhao Ge, Liang Chen, et al.
The Lancet. Infectious Diseases
|
November 12, 2021
Clinical outcomes and bacterial characteristics of carbapenem-resistant Klebsiella pneumoniae complex among patients from different global regions (CRACKLE-2): a prospective, multicentre, cohort study
Minggui Wang, Michelle Earley, Liang Chen, et al.
The Lancet. Microbe
|
February 12, 2023
Global epidemiology and clinical outcomes of carbapenem-resistant Pseudomonas aeruginosa and associated carbapenemases (POP): a prospective cohort study
Jinnethe Reyes, Lauren Komarow, Liang Chen, et al.
JAMA
|
August 13, 2025
Dalbavancin for Treatment of Staphylococcus aureus Bacteremia: The DOTS Randomized Clinical Trial
Nicholas A Turner, Toshimitsu Hamasaki, Sarah B Doernberg, et al.
Page
of 52